Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Plerixafor: does weight-based or fixed-dose affect hematopoietic stem cell movement in non-Hodgkin’s lymphoma?

Posted by on Jul 16, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of fixed-dose (FD) and weight-based (WB) dose plerixafor (Mozobil) on hematopoietic stem cell (HSC) movement in patients with Non-Hodgkin’s lymphoma (NHL) weighing less than 11 stone. The main finding was that there was no significant difference in HSC movement with WB or FD plerixafor. Some...

Read More

Management of DLBCL patients at high risk of brain metastasis

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This article reviewed the treatment options for patients with very high-risk diffuse large B-cell lymphoma (DLBCL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. DLBCL patients with certain risk factors may develop relapsed disease in the brain. The...

Read More

Management of DLBCL patients at high risk of brain metastasis

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This article reviewed the treatment options for patients with very high-risk diffuse large B-cell lymphoma (DLBCL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. DLBCL patients with certain risk factors may develop relapsed disease in the brain. The...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Is pirarubicin safer and more effective than doxorubicin in R-CHOP for diffuse large B-cell lymphoma?

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of two first-line chemotherapy regimens for diffuse large B-cell lymphoma. This study concluded that the R-THP-COP regimen was as effective as conventional R-CHOP for diffuse large B-cell lymphoma. Some background R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine,...

Read More

Comparing survival outcomes for elderly DLBCL patients receiving different first-line chemotherapies

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of different chemotherapies on the survival outcomes of elderly patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CHOP treatment is associated with very good survival in elderly patients with DLBCL. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...

Read More

Comparing survival outcomes for elderly DLBCL patients receiving different first-line chemotherapies

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the effects of different chemotherapies on the survival outcomes of elderly patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that R-CHOP treatment is associated with very good survival in elderly patients with DLBCL. Some background Diffuse large B-cell lymphoma (DLBCL) is the most common...

Read More

Pre-stem cell transplant BEAM versus FEAM for non-Hodgkin’s lymphoma

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of BEAM (carmustine, etoposide, cytarabine, melphalan) and FEAM (fotemustine instead of carmustine) chemotherapy regimens in patients with non-Hodgkin's lymphoma. This study concluded that these regimens are similarly effective, but FEAM was associated with more severe side effects. Some...

Read More

Pre-stem cell transplant BEAM versus FEAM for non-Hodgkin’s lymphoma

Posted by on Jul 15, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study compared the safety and effectiveness of BEAM (carmustine, etoposide, cytarabine, melphalan) and FEAM (fotemustine instead of carmustine) chemotherapy regimens in patients with non-Hodgkin's lymphoma. This study concluded that these regimens are similarly effective, but FEAM was associated with more severe side effects. Some...

Read More

Chemotherapy after radiotherapy for early-stage follicular lymphoma

Posted by on Jul 14, 2018 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study investigated the safety and effectiveness of systemic chemotherapy after radiotherapy for early-stage follicular lymphoma. This study concluded that this combined treatment is more effective than radiotherapy alone for early-stage follicular lymphoma. Some background Radiotherapy can help control local disease in more than 90%...

Read More